ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumours: Results of a Phase I trial

Research output: Contribution to journalArticle


  • M Ronson
  • M Kris
  • A Tullo
  • V Miller
  • S Averbuch
  • J Ochs
  • C Morris
  • A Feyereislova
  • H Swaisland
  • EK Rowinsky

Colleges, School and Institutes


Original languageEnglish
Pages (from-to)2240-2250
Number of pages11
JournalJournal of Clinical Oncology
Issue number9
Publication statusPublished - 1 May 2002